PD-1 Combo don’t fail because of biology
They fail because they don’t scale
Most regimens are designed for maximum efficacy in controlled settings — but break when deployed in real-world oncology practice.
The Approach
We focus on engineering PD-1 Combo where deployability is built into the design — not managed after toxicity emerges.
By targeting suppressive myeloid biology to restore T-cell function, we aim to improve efficacy without adding to the toxicity burden that limits real-world community use.